ScoreWhy is Arbutus Biopharma Corp. ?
1
With a growth in Net Sales of 508.79%, the company declared Very Positive results in Jun 25
- OPERATING CASH FLOW(Y) Highest at USD -59.64 MM
- RAW MATERIAL COST(Y) Fallen by -26.2% (YoY)
- NET SALES(Q) Highest at USD 10.74 MM
2
High Institutional Holdings at 62.35%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 4.45% over the previous quarter.
3
Market Beating Performance
- The stock has generated a return of 26.32% in the last 1 year, much higher than market (S&P 500) returns of 12.33%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Arbutus Biopharma Corp. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Arbutus Biopharma Corp. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Arbutus Biopharma Corp.
29.33%
0.84
44.70%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
14.96%
EBIT Growth (5y)
5.33%
EBIT to Interest (avg)
-46.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.36
Sales to Capital Employed (avg)
0.13
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
62.35%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.42
EV to EBIT
-8.76
EV to EBITDA
-8.95
EV to Capital Employed
-19.55
EV to Sales
87.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-72.94%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend35What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -59.64 MM
RAW MATERIAL COST(Y)
Fallen by -26.2% (YoY
NET SALES(Q)
Highest at USD 10.74 MM
OPERATING PROFIT(Q)
Highest at USD 1.92 MM
OPERATING PROFIT MARGIN(Q)
Highest at 17.92 %
PRE-TAX PROFIT(Q)
Highest at USD 2.95 MM
NET PROFIT(Q)
Highest at USD 2.95 MM
EPS(Q)
Highest at USD 0.01
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Arbutus Biopharma Corp.
Net Sales
At USD 10.74 MM has Grown at 570.87%
over average net sales of the previous four periods of USD 1.6 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -59.64 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD 2.95 MM has Grown at 120.42%
over average net sales of the previous four periods of USD -14.43 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 2.95 MM has Grown at 120.42%
over average net sales of the previous four periods of USD -14.43 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Highest at USD 10.74 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 1.92 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 17.92 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 2.95 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 2.95 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.01
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -26.2% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Arbutus Biopharma Corp.
Non Operating Income
Highest at USD 0.42 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
